What Just Happened With Ingevity (NGVT)?

Simply Wall St · 11/09 06:27

What Ingevity’s latest earnings tell you

Ingevity (NGVT) just released third quarter and nine month results, giving investors fresh numbers on profitability, revenue mix, and the ongoing reshaping of its portfolio.

The chemicals producer reported third quarter sales of US$305.1 million compared with US$333.1 million a year earlier, while net income came in at US$49.3 million against US$43.5 million in the prior period. Basic earnings per share from continuing operations reached US$1.49 compared with US$1.12, with diluted earnings per share from continuing operations at US$1.46 compared with US$1.10.

On a total basis, basic earnings per share were US$1.44 compared with US$1.20 a year ago, and diluted earnings per share were US$1.41 compared with US$1.18. Management attributed the changed revenue profile in part to portfolio moves, including a divestiture that affected top line figures while adjusted profit margins expanded, supported by filtration demand and North American hybrid vehicle production.

For the first nine months of 2026, Ingevity recorded sales of US$877.2 million compared with US$912.5 million in the same period of 2025. Net income for the period was US$144.4 million compared with a net loss of US$82.5 million a year ago, with basic earnings per share from continuing operations at US$3.29 versus a basic loss per share from continuing operations of US$1.97, and diluted earnings per share from continuing operations at US$3.23 versus a diluted loss per share from continuing operations of US$1.97.

Including all operations, basic earnings per share for the nine months reached US$4.16 compared with a basic loss per share of US$2.27, and diluted earnings per share were US$4.08 compared with a diluted loss per share of US$2.27. These swings highlight how different the income statement looks versus last year even with softer sales, which matters if you are trying to separate operational progress from portfolio cleanup.

Alongside the results, the business issued full year 2026 guidance calling for net sales of approximately US$1.1b. That target gives investors a rough sense of scale for the current year after recent divestiture activity and ongoing discussions around the Advanced Polymer Technologies segment.

Management also flagged that the sale process for Advanced Polymer Technologies is taking longer than initially expected and could extend into early 2027, even though the aim is still to announce a transaction before the end of 2026. For anyone watching Ingevity, the timing and terms of a potential deal for this unit are likely to influence how cleanly investors can model the remaining Performance Materials and Performance Chemicals segments.

Higher asphalt costs are pressuring the pavement focused part of the Performance Chemicals segment, and that pressure could slow growth in warm mix asphalt offerings in 2027. If you follow Ingevity for its exposure to infrastructure and road spending, that comment adds another variable to assess when weighing the durability of earnings from the road technologies portfolio.

Ingevity’s shares have slipped in the short term, with the 1 day share price return down 5.63% and the 7 day share price return down 18.44% heading into these results, even as the 1 year total shareholder return sits at 20.58% and the 3 year total shareholder return at 60.02%. This signals that long term holders have still seen meaningful gains despite fading recent momentum.

Spot similar materials players that could be setting up for the next move by scanning our hand picked 39 high quality undervalued stocks with resilient cash flows and stronger balance sheets than Ingevity.

Bulls see Ingevity’s margin rebuild and portfolio reshaping as mispriced after the pullback. Bears point to softer sales and asphalt headwinds. Which story do the current valuation markers lean toward?

Preferred P/E of 57.2x for Ingevity: Is it justified?

On simple valuation math, Ingevity does not screen as cheap. At the last close of $60.12, the stock is trading on a P/E of 57.2x, while the broader US Chemicals industry comes in at 23.4x and the peer group average sits at 48.5x.

The P/E ratio compares the share price with earnings per share. For a materials producer like Ingevity, it reflects how much investors are willing to pay today for each dollar of profit, based on expectations for earnings durability and any future growth that might already be baked into the price.

Here the market is paying a premium. The P/E of 57.2x sits well above the sector average of 23.4x and also above the estimated fair P/E of 31.4x from the SWS model. That gap suggests the current multiple is rich compared with where valuation could reasonably settle if sentiment normalises and earnings quality, including one off items and the use of higher risk debt funding, remain key issues investors monitor.

Explore the SWS fair ratio for Ingevity.

Result: Price-to-earnings of 57.2x (OVERVALUED)

Still, the recent 22.7% slide over 90 days and the longer than expected Advanced Polymer Technologies sale process could both unsettle confidence in the current Ingevity valuation story.

Find out about the key risks to this Ingevity narrative.

Another view on Ingevity’s value

The earnings based P/E looks steep for Ingevity, yet the SWS DCF model tells a very different story. On that framework, the estimated future cash flow value sits at $168.9 per share versus the current $60.12. This implies the market price is well below that cash flow based estimate.

If you lean on cash generation rather than headline earnings, this gap can look like either a valuation cushion or a signal that assumptions inside the model need closer inspection before you act on it.

Look into how the SWS DCF model arrives at its fair value.

NGVT Discounted Cash Flow as at Nov 2026
NGVT Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ingevity for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 39 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of upbeat and cautious signals around Ingevity leaves plenty of room for debate, so act while the details are fresh and form your own take using the 4 key rewards and 3 important warning signs

Looking for more investment ideas beyond Ingevity?

Do not stop with Ingevity. Fresh opportunities often sit just outside your current watchlist, and a quick screen can surface ideas you would otherwise miss.